What is NAGE's health score?

Niagen Bioscience, Inc. (NAGE) has a TradeApes health score of 64 out of 100, rated Healthy. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is NAGE's estimated fair value?

Based on our 5-year discounted cash flow model, Niagen Bioscience, Inc.'s estimated fair value is $5.06 per share, representing a 45.5% upside from the current price. This is a model estimate, not a price target or investment recommendation.

Is NAGE undervalued or overvalued?

Our model currently rates NAGE as Undervalued. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for NAGE... Refresh in a moment for the full analysis.

Niagen Bioscience, Inc. (NAGE)

Healthcare Undervalued low healthy

$3.48

Updated: 2026-06-04

TradeApes Score

Financial Strength

75 Strong

Operating Trend

68 Healthy

Relative Value

50 Mixed

Capital Allocation

50 Mixed

Risk

80 Strong

Est. Fair Value $5.06

DCF Upside +45.5%

Sector Rank #1609 of 6850

Key Findings

+ Strong revenue growth — sales up more than 20% year over year

Unlock Full Report →

− FCF deteriorating — free cash flow down more than 25% year over year

Unlock Full Report →

Create an account for unlimited access

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.